Answers are grounded in this paper and cite their sources.
In August of 1897 Felix Hoffmann, working at the Bayer factory in Germany, developed aspirin. He synthesised the acetylated form of salicylic acid as a treatment for his father’s arthritis and since then aspirin has become the most widely used medicine of all time [1]. Around 35 years later, the French physician Widal first described the association of aspirin sensitivity, asthma and nasal polyps [2], a phenomenon further popularized by Samter and Beer [3] in 1968. Aspirin-sensitive respiratory disease (ASRD) is a phenotype of asthma that may be aggressive and refractory to treatment. Patients with ASRD are over-represented in the severe asthma group and 50% of the patients with aspirin sensitivity are steroid dependent [4].ASRD affects women more frequently than men. Rhinorrhoea and nasal congestion are usually the first symptoms. Furthermore, the condition is rare in childhood with the peak age of onset in the early 30s. It is a condition that progresses from the upper to the lower respiratory tract and asthma manifests around 1–5 years after the onset of rhinitis [5].The aetiology of ASRD is complex but most investigators are agreed that the reaction to aspirin is not mediated by allergic mechanisms. Most evidence points towards an abnormality of arachidonic acid (AA) metabolism. AA is a substrate for both the production of leucotrienes (LTs) via the 5-lipoxygenase (5-LO) pathway and of prostanoids via the cyclo-oxygenase (COX) pathway.The hallmark of ASRD is excessive cysteinyl (Cys) LT production both in the steady state and for several hours after aspirin challenge [6]. Urinary LTE4 levels, as a measure of the total body production of CysLTs, are a mean 6-fold higher in patients with ASRD and still increasing 4-fold higher after aspirin challenge [7].To date, the question of whether ASRD is associated with a fundamental, predetermined abnormality in the production of CysLTs or whether it is simply a consequence of greater numbers and the activation of granulocytes, such as eosinophils and mast cells [8, 9], remains unanswered – although these possibilities are not mutually exclusive. It has been reported that the numbers of cells immunoreactive for LTC4 synthase are significantly elevated a prioriin the bronchial mucosa of aspirin-sensitive patients, as compared with aspirin-tolerant patients [10]. The expression of LTC4 synthase in aspirin-sensitive patients correlated with the patients’ bronchial response to aspirin challenge [10]. Genetic polymorphisms of the LTC4 synthase gene which result in an elevated expression of this enzyme may play a role [11] but other not yet identified genetic regulatory mechanisms may also contribute.Recent evidence suggests that stem cell factor (SCF), a cytokine chemotactic for mast cells and important mast cell growth factor, is released in increasing quantities by epithelial cells in aspirin-sensitive compared with aspirin-tolerant patients. The expression of SCF in epithelial cells and the density of mast cells in nasal polyp tissue correlated with the number of nasal polypectomies in aspirin-sensitive patients, suggesting a pathophysiological link between SCF, mast cells and the severity of nasal polyposis [12].Almost 60 years after the discovery of CysLTs, 2 G-protein-coupled receptors, CysLT receptor 1 (CysLT1) and CysLT receptor 2 (CysLT2), were cloned and sequenced [13, 14]. Both receptors bind to CysLTs with the affinity order of LTD4 > LTC4 > > LTE4 (CysLT1) and LTD4 = LTC4 > > LTE4 (CysLT2) and both are expressed on smooth muscle cells and inflammatory leucocytes.The discovery of the 2 receptors rapidly opened the way for experiments to determine whether the expression of CysLT1 or CysLT2 differed in patients with aspirin sensitivity compared to their aspirin-tolerant counterparts. Sousa et al. [15] reported in 2002 that there is up-regulation in CysLT1 expression in nasal biopsies from aspirin-sensitive patients, which was not seen for CysLT2[16]. Desensitization with aspirin improved clinical sensitivity to aspirin and was associated with a down-regulation of the CysLT1 in nasal inflammatory cells [15] but not in the production of CysLTs [17]. In contrast, the percentages of cells expressing the LTB4 receptor did not vary between the groups [15].The results of Sousa et al. [15], may explain why subjects with ASRD demonstrate greater airway responsiveness to aerosolized LTE4 than non-aspirin-sensitive subjects [18]. In contrast to LTE4, there was no significant difference in the airway responsiveness to inhaled LTC4 and LTD4. This is intriguing because CysLT1 binds LTD4 > LTC4 > > LTE4. It has been speculated that there may be further CysLT receptors or heterodimers yet to be discovered or that post-receptor signalling may be differentially regulated in a ligand-specific fashion.Thus ASRD is characterized not only by an overproduction of CysLTs but also by an increased expression of CysLT1 on eosinophils and mast cells in the airway mucosa, which would be expected to enhance the ability of CysLTs to activate these cells. In light of these experimental data, Sousa et al. [15] have proposed that ASRD is best explained by a 2-compartment model with both enhanced mediator release and altered target organ responsiveness [15]. The findings that 5-LO inhibitors and CysLT1 antagonists attenuate aspirin-induced asthmatic attacks [19,20,21] prove the central role of CysLTs and CysLT1 in ASRD.Prostaglandins are produced from AA by the action of COX enzymes. COX enzymes exist as 2 main isoforms: COX-1 is the constitutive enzyme responsible for the synthesis of protective prostanoids, whereas COX-2 is induced under inflammatory conditions; both proteins are encoded by 2 different genes. More recently, additional COX enzymes have been discovered: COX-3 and 2 smaller isoforms of COX-1 [22].Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 precipitate acute rhinosinusitis and asthma in aspirin-sensitive patients. The capacity of an NSAID to precipitate asthma in susceptible subjects is related to its potency in inhibiting COX-1.During the late 1990s, a new class of anti-inflammatory drugs selectively designed to act on COX-2 was introduced. Numerous clinical trials have confirmed the broad safety of this class of drugs in aspirin-sensitive patients [23,24,25]. COX-2 inhibitors may therefore be safer to use in patients with ASRD than acetaminophen which cross-reacts with aspirin in 20–30% of the aspirin-sensitive patients. The paper by Bavbek et al. [26] published in this issue further confirms the relative safety of meloxicam in patients with ASRD. Twenty-one patients with ASRD were challenged with meloxicam. Twenty patients tolerated meloxicam with no adverse effects, 1 patient developed severe bronchospasm with a 33% reduction in the forced expiratory volume in 1 s. The authors conclude that meloxicam is a generally safe analgesic in patients with ASRD but should be prescribed only if the patient has undergone a negative meloxicam challenge.Prostaglandin E2 (PGE2) has immunomodulatory effects [27, 28] which include: inhibiting the early and late bronchoconstrictor response to inhaled allergen [29]; inhibition of eosinophil activation, chemotaxis and cytokine-stimulated survival; inhibition of mast cell degranulation [28,30,31,32]. Furthermore, PGE2 blocks the release of CysLTs from cultured blood leucocytes from aspirin-sensitive patients [33]. Aerosolized PGE2 abolishes aspirin-induced bronchoconstriction and up-regulation of CysLT production [34]. The mechanism for the inhibition of CysLT biosynthesis may be secondary to the inhibition of 5-LO translocation to the nucleus [35].Inhibition of the synthesis of PGE2 by NSAIDs may thusprovide one important mechanism for aspirin-induced exacerbations of asthma and rhinitis. However, the key question is why this phenomenon is not observed in all patients with asthma and chronic polypoid rhinosinusitis but only in those who are aspirin sensitive.It has been hypothesized that perhaps patients with ASRD are particularly dependent on a PGE2-induced ‘braking’ of CysLT production [36]. Excessive CysLT production in ASRD may reflect deficient PGE2 production and/or abnormal PGE2 receptor expression or signalling.Studies addressing PGE2 production in aspirin-sensitive patients so far have involved the analysis of peripheral blood cells, which are remote from the site of the disease [33], or of prolonged cultures of tissue in vitro [37, 38], and further work is required.There are 4 G-protein-coupled PGE2 receptors designated EP1–4[39]. Stimulation of EP1 results in the activation of phosphatidyl inositol hydrolysis and an elevation of intracellular Ca2+ concentrations. EP2 and EP4 ligation increases intracellular cyclic AMP, whereas EP3 ligation decreases it.In a recent study, EP receptor expression in ASRD was examined [40]. Global mucosal expression of EP1 and EP2, but not EP3 and EP4, was increased in nasal biopsies from both aspirin-sensitive and non-aspirin-sensitive patients compared with normal controls. This is an interesting observation as PGE2 protects epithelial cells from injury and promotes wound healing and repair in the gastro-intestinal and respiratory tracts [41, 42], consistent with a general response to inflammation.Despite a global increased expression of EP2 in the nasal epithelium in aspirin-sensitive and aspirin-tolerant rhinosinusitis, a reduction of the expression of this receptor was seen in a wide range of mucosal inflammatory leucocytes including eosinophils, neutrophils, mast cells and T cells in the aspirin-sensitive patients. The overall numbers of these cells (particularly eosinophils) were elevated in the aspirin-sensitive group.PGE2 interacts with EP2 to inhibit human lung mast cell activity [43] and a functional single nucleotide polymorphism of the EP2 gene [44] is associated with an increased risk of aspirin-sensitive asthma and rhinosinusitis. This single nucleotide polymorphism is believed to be associated with a decrease in the transcription level of the receptor.PGE2 therefore has the potential to reverse 3 of the cardinal features of ASRD: enhanced CysLT production, smooth muscle hyperplasia (smooth muscle cells from asthmatic patients over-express PGE2 receptors) and epithelial damage of the airways.In addition to the 5-LO pathway, there is dysregulation of other LOs in ASRD. For instance 15S-hydroxyeicosatetraenoic acid (HETE) is generated by the metabolism of AA by 15-LO. Peripheral blood leucocytes from aspirin-sensitive patients exposed to aspirin produce more 15S-HETE compared to aspirin-tolerant patients [45] and it has even been suggested that this could be used as an in vitro test for aspirin sensitivity [46]. The role of this metabolite in the pathogenesis of ASRD, however, is uncertain since CysLT1 antagonists and 5-LO inhibitors block aspirin-induced asthmatic reactions.Lipoxins (LXs) are double LO products derived from interactions between 5-, 12- and 15-LO and, in contrast to CysLTs, they have anti-inflammatory actions. Inhalation of LXA4 in human asthmatics blocked LTC4-stimulated bronchoconstriction [47] and LXA4 inhibits cellular migration [48, 49]. Patients with ASRD generate less LXA4 relative to CysLTs than aspirin-tolerant asthmatics [50], suggesting that anti-inflammatory mechanisms in ASRD may be deficient.In addition to inhibiting COX, aspirin acetylates COX-2 and generates 15R-HETE, a biosynthetic precursor for 15-epi-LXA4[51]. Peripheral blood of patients with ASRD has a diminished biosynthetic capacity for 15-epi-LXA4, a 5-LO product of 15R-HETE. Since 15-epi-LXA4 is more potent than native LXA4 as inhibitors of polymorphonuclear leucocyte trafficking and polymorphonuclear-leucocyte-mediated inflammation in vivo [52], a reduced generation of 15-epi-LXA4 may result in further decreased anti-inflammatory mechanisms in ASRD.ASRD is a relatively common phenotype of asthma, affecting around 10% of all asthmatics. It remains difficult to treat and its pathogenesis remains only partially understood. The mechanism is best explained by a 2-compartment model of enhanced CysLT production and altered end organ responsiveness. Key features of this condition include an increased CysLT production both at baseline and subsequent to aspirin challenge, the flooding of the nasal and bronchial mucosa with eosinophils and mast cells both prior to and as a result of aspirin challenge, an elevated expression of CysLT1 and decreased EP2 in the nasal mucosa, and the ability of patients with ASRD to tolerate selective COX-2 antagonists.A fuller understanding of the mechanisms of this condition may inform new treatments. For instance, stable analogues of PGE2 and LXs could be developed and tested in ASRD, a condition that can be life-threatening and is a source of considerable morbidity.
No takes yet. Share an insight, caveat, or question.
Farooque et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: